Biblioteca Humberto Rosselli Quijano
Información del autor
Autor Vittorino Andreoli |
Documentos disponibles escritos por este autor (1)
Refinar búsqueda
Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression / Vittorino Andreoli en Journal of Clinical Psychopharmacology, Año 2002 - Vol. 22 - No. 4 (Agosto)
[artículo]
Título : Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression Tipo de documento: texto impreso Autores: Vittorino Andreoli, Autor ; Vincent Caillard, Autor ; Ripu S. Deo, Autor Fecha de publicación: 2023 Artículo en la página: pp. 393-399 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antidepresivos, Trastorno depresivo mayor, Fluoxetina, Morfolinas, Reboxetina, Inhibidores selectivos de la recaptación de serotonina. Resumen: The clinical profile of reboxetine, a selective noradrenaline reuptake inhibitor, was compared with that of the selective serotonin reuptake inhibitor fluoxetine and placebo in a double-blind, multicenter, parallel-group clinical trial of patients with major depression. Link: ./index.php?lvl=notice_display&id=31056
in Journal of Clinical Psychopharmacology > Año 2002 - Vol. 22 - No. 4 (Agosto) . - pp. 393-399[artículo] Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression [texto impreso] / Vittorino Andreoli, Autor ; Vincent Caillard, Autor ; Ripu S. Deo, Autor . - 2023 . - pp. 393-399.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2002 - Vol. 22 - No. 4 (Agosto) . - pp. 393-399
Palabras clave: Antidepresivos, Trastorno depresivo mayor, Fluoxetina, Morfolinas, Reboxetina, Inhibidores selectivos de la recaptación de serotonina. Resumen: The clinical profile of reboxetine, a selective noradrenaline reuptake inhibitor, was compared with that of the selective serotonin reuptake inhibitor fluoxetine and placebo in a double-blind, multicenter, parallel-group clinical trial of patients with major depression. Link: ./index.php?lvl=notice_display&id=31056